Insider Monkey
Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress
📈
AI Sentiment
Highly Positive
8/10
- Home
- ZURA
ZURA
Zura Bio Limited
as of 12-02-2025 4:00pm EST
$3.51
$0.21
-5.65%
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Chart Type:
Time Range:
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 137.2M | IPO Year: | N/A |
| Target Price: | $11.38 | AVG Volume (30 days): | 408.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $4.68 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ZURA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 68.87%
68.87%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Zura Bio Limited News
ZURA Breaking Stock News: Dive into ZURA Ticker-Specific Updates for Smart Investing
Compare ZURA vs Leading Stocks
See how ZURA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ZURA Zura Bio Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.